375 related articles for article (PubMed ID: 18272515)
1. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis.
Cornely OA; Böhme A; Reichert D; Reuter S; Maschmeyer G; Maertens J; Buchheidt D; Paluszewska M; Arenz D; Bethe U; Effelsberg J; Lövenich H; Sieniawski M; Haas A; Einsele H; Eimermacher H; Martino R; Silling G; Hahn M; Wacker S; Ullmann AJ; Karthaus M;
J Antimicrob Chemother; 2008 Apr; 61(4):939-46. PubMed ID: 18272515
[TBL] [Abstract][Full Text] [Related]
2. Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis.
Kaya Z; Gursel T; Kocak U; Aral YZ; Kalkanci A; Albayrak M
Pediatr Blood Cancer; 2009 Apr; 52(4):470-5. PubMed ID: 19058205
[TBL] [Abstract][Full Text] [Related]
3. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
[TBL] [Abstract][Full Text] [Related]
4. Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis.
Lewis G; Hall P; Eisa N; Deremer D; Dobbins R; El-Geneidy M; Jillella A; Ustun C
Acta Haematol; 2010; 124(4):206-13. PubMed ID: 21071929
[TBL] [Abstract][Full Text] [Related]
5. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
Maertens J
Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
[TBL] [Abstract][Full Text] [Related]
6. Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases.
Malagola M; Peli A; Damiani D; Candoni A; Tiribelli M; Martinelli G; Piccaluga PP; Paolini S; De Rosa F; Lauria F; Bocchia M; Gobbi M; Pierri I; Zaccaria A; Zuffa E; Mazza P; Priccolo G; Gugliotta L; Bonini A; Visani G; Skert C; Bergonzi C; Roccaro AM; Filì C; Fanin R; Baccarani M; Russo D
Eur J Haematol; 2008 Nov; 81(5):354-63. PubMed ID: 18637030
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
[TBL] [Abstract][Full Text] [Related]
8. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.
Kern W; Behre G; Rudolf T; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W
Cancer; 1998 Jul; 83(2):291-301. PubMed ID: 9669812
[TBL] [Abstract][Full Text] [Related]
9. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.
Jansen J; Akard LP; Wack MF; Thompson JM; Dugan MJ; Leslie JK; Mattison R
Mycoses; 2006 Sep; 49(5):397-404. PubMed ID: 16922792
[TBL] [Abstract][Full Text] [Related]
10. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
11. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years.
Hovi L; Saarinen-Pihkala UM; Vettenranta K; Saxen H
Bone Marrow Transplant; 2000 Nov; 26(9):999-1004. PubMed ID: 11100280
[TBL] [Abstract][Full Text] [Related]
12. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation.
Dvorak CC; Steinbach WJ; Brown JM; Agarwal R
Bone Marrow Transplant; 2005 Oct; 36(7):621-9. PubMed ID: 16044133
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic SCT in patients with a history of invasive fungal infection.
Zhang P; Song A; Wang Z; Feng S; Qiu L; Han M
Bone Marrow Transplant; 2009 Apr; 43(7):533-7. PubMed ID: 19104496
[TBL] [Abstract][Full Text] [Related]
14. [Invasive fungal infections in patients with blood disorders].
López F; Jarque I; Martín G; Sanz GF; Palau J; Martínez J; de la Rubia J; Larrea L; Arnao M; Solves P; Cervera J; Martínez ML; Pemán J; Gobernado M; Sanz MA
Med Clin (Barc); 1998 Mar; 110(11):401-5. PubMed ID: 9608494
[TBL] [Abstract][Full Text] [Related]
15. Antifungal treatment strategies in high risk patients.
Rüping MJ; Vehreschild JJ; Cornely OA
Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
[TBL] [Abstract][Full Text] [Related]
16. Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China.
Wang L; Hu J; Sun Y; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
Medicine (Baltimore); 2016 Jan; 95(4):e2560. PubMed ID: 26825897
[TBL] [Abstract][Full Text] [Related]
17. [Prophylaxis use of posaconazole (P) in an hemato-oncology unit: a retrospective study].
Selvy N; Villiet M; Hansel-Esteller S
Pathol Biol (Paris); 2010 Apr; 58(2):123-6. PubMed ID: 19864087
[TBL] [Abstract][Full Text] [Related]
18. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study.
Slobbe L; Polinder S; Doorduijn JK; Lugtenburg PJ; el Barzouhi A; Steyerberg EW; Rijnders BJ
Clin Infect Dis; 2008 Dec; 47(12):1507-12. PubMed ID: 18990068
[TBL] [Abstract][Full Text] [Related]
19. Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders.
Hovi L; Saxen H; Saarinen-Pihkala UM; Vettenranta K; Meri T; Richardson M
Pediatr Blood Cancer; 2007 Jan; 48(1):28-34. PubMed ID: 16395687
[TBL] [Abstract][Full Text] [Related]
20. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
Maertens J; Theunissen K; Verhoef G; Verschakelen J; Lagrou K; Verbeken E; Wilmer A; Verhaegen J; Boogaerts M; Van Eldere J
Clin Infect Dis; 2005 Nov; 41(9):1242-50. PubMed ID: 16206097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
